Gram Research analysis shows that two new experimental drugs, LL-M and LL-P, reduced weight gain and improved blood sugar control in obese mice by restoring energy production in fat cells. In a 2026 preclinical study, these compounds blocked proteins that normally destroy mitochondria, the cellular power plants. However, this is very early laboratory research, and these drugs do not exist for human use yet.
Scientists have discovered two new experimental drugs, called LL-M and LL-P, that may help fight obesity by fixing broken energy factories inside fat cells. In lab tests and mice studies, these drugs improved how the body burns calories and handles blood sugar. The research, published in October 2026, suggests these compounds could one day become treatments for obesity and related health problems. However, these are very early findings, and much more testing in humans is needed before anyone could use these drugs.
Key Statistics
A 2026 preclinical study found that two novel STK3/4 inhibitors, LL-M and LL-P, attenuated body-weight gain and improved glucose tolerance in high-fat diet-fed male mice after just 2 weeks of treatment.
According to research reviewed by Gram, the experimental drugs LL-M and LL-P enhanced energy expenditure in obese mice by restoring mitochondrial metabolic activity through suppression of BNIP3-mediated mitophagy.
In laboratory-grown fat cells, both LL-M and LL-P effectively suppressed STK3/4 signaling and reduced the destruction of mitochondria, leading to increased cellular energy production capacity.
The Quick Take
- What they studied: Whether two new experimental drugs could help treat obesity by restoring how fat cells produce energy
- Who participated: Lab-grown fat cells and male mice fed either normal food or a high-fat diet for 2 weeks of treatment
- Key finding: Both drugs reduced weight gain, improved blood sugar control, and boosted energy burning in obese mice
- What it means for you: This is very early research in animals and cells only. These drugs do not exist for human use yet, and years of testing would be needed before they could become real medicines. Do not expect these treatments anytime soon.
The Research Details
Researchers started by screening thousands of small molecules to find two compounds, LL-M and LL-P, that could block proteins called STK3 and STK4. These proteins normally tell fat cells to destroy their mitochondria, which are the energy-producing structures inside cells. The team first tested these drugs in lab-grown fat cells to see if they worked as expected. Then they moved to live mice, feeding some a normal diet and others a high-fat diet to mimic obesity. After 2 weeks of treatment with either drug, they measured body weight, blood sugar response, and how much energy the mice burned.
This type of research is called preclinical testing because it happens before any human trials. Scientists use it to understand how a drug works and whether it shows enough promise to test in people. The researchers chose to study STK3 and STK4 because previous work suggested these proteins play a role in obesity by damaging mitochondria in fat tissue.
The study design allowed researchers to test both whether the drugs worked in isolated cells and whether they worked in living animals with real obesity. This two-step approach helps confirm that a drug’s effects in a dish actually translate to benefits in a whole body.
Understanding how mitochondria work in fat cells is important because broken mitochondria may be one reason why obese people struggle to lose weight and control blood sugar. If scientists can fix this problem with a drug, it could offer a new way to treat obesity that works differently from current medications. This research matters because it identifies a specific target, STK3/4, that hasn’t been heavily explored for obesity treatment before.
This is early-stage laboratory and animal research, which means the findings are preliminary. The study was published in a peer-reviewed journal, which is good, but peer review doesn’t guarantee the results will hold up in humans. The researchers used standard lab techniques and mouse models commonly used in obesity research. However, the abstract does not specify how many mice were tested, which is important information for evaluating the strength of the findings. Results in mice often do not translate to humans, so this work is far from becoming a real treatment.
What the Results Show
In fat cells grown in the laboratory, both LL-M and LL-P successfully blocked STK3 and STK4 proteins. This blocking action reduced a process called mitophagy, which is when cells destroy their mitochondria. By reducing this destruction, the drugs allowed mitochondria to stay active and produce more energy. The researchers measured this by looking at markers of mitochondrial activity, which increased when the drugs were present.
In mice fed a high-fat diet, treatment with either drug for 2 weeks produced measurable benefits. The mice that received LL-M or LL-P gained less weight compared to untreated mice on the same high-fat diet. Their bodies also became better at handling glucose, a sign of improved insulin sensitivity. Additionally, the treated mice burned more calories at rest, meaning their metabolic rate increased.
These results suggest that blocking STK3 and STK4 can restore mitochondrial function in fat tissue, which then improves overall metabolism. The fact that both drugs showed similar benefits suggests the effect is real and not due to chance.
The study found that the drugs worked by a specific mechanism: they reduced BNIP3-mediated mitophagy, which is the cellular process that destroys mitochondria. This is important because it shows the drugs work through the pathway the researchers predicted. The improvement in glucose tolerance is particularly significant because poor blood sugar control is a major health problem in obesity. Enhanced energy expenditure is also noteworthy because it means the body was burning more fuel, which could lead to weight loss over time.
Previous research has shown that mitochondrial dysfunction contributes to obesity and metabolic disease. This study builds on that knowledge by identifying STK3 and STK4 as specific targets that could be blocked to improve mitochondrial function. Most current obesity drugs work through different mechanisms, such as reducing appetite or slowing fat absorption. This research represents a novel approach focused on fixing the energy-production problem at the cellular level. The findings align with growing interest in mitochondrial health as a target for metabolic disease treatment.
This research has several important limitations. First, it was conducted only in cells and mice, not in humans. Mouse metabolism differs from human metabolism in important ways, so results may not translate. Second, the treatment period was only 2 weeks, which is very short. Real obesity treatment would need to work over months or years. Third, the abstract does not specify the number of mice tested, making it hard to judge how reliable the results are. Fourth, these are completely new experimental drugs with no safety data in any living system yet. Finally, the study does not address whether the drugs would have side effects or how they would be delivered to patients.
The Bottom Line
At this stage, there are no recommendations for human use. This is basic research that may eventually lead to new treatments, but that is years away. People with obesity should continue working with their doctors on proven approaches like diet, exercise, and existing medications. Confidence level: Not applicable, as this research is preclinical only.
Researchers studying obesity and mitochondrial disease should pay attention to this work. People with obesity or metabolic disorders may find this interesting as a potential future option, but should not expect these drugs to become available soon. Healthcare providers should be aware of this research direction but should not mention these specific drugs to patients yet.
If these drugs move forward, the typical path would be 3 to 5 years of additional laboratory testing, followed by 5 to 10 years of human clinical trials before potential approval. Realistically, these specific compounds may never reach patients if safety or effectiveness issues emerge. Even if successful, the earliest these could become available would be 8 to 15 years from now.
Frequently Asked Questions
Can I use these new obesity drugs LL-M and LL-P right now?
No, these drugs exist only in laboratory and animal testing stages. They have never been tested in humans and are not approved for any use. Years of additional research and clinical trials would be needed before they could potentially become available as medicines.
How do these obesity drugs work differently from current weight loss medications?
LL-M and LL-P target mitochondrial function in fat cells by blocking STK3 and STK4 proteins. Most current obesity drugs work through appetite suppression or fat absorption reduction. This represents a novel approach focused on fixing the energy-production problem at the cellular level.
What does it mean that these drugs improved glucose tolerance in mice?
Improved glucose tolerance means the body handled blood sugar better after receiving the drugs. This is important because poor blood sugar control is a major problem in obesity and can lead to type 2 diabetes. Better glucose control suggests these drugs might help prevent or manage metabolic disease.
Why should I care about mitochondrial function for weight loss?
Mitochondria are the energy factories inside cells. When they work poorly, your body burns fewer calories and stores more fat. Fixing mitochondrial function could help your body burn more energy naturally, making weight management easier. This is why researchers are exploring this approach.
How long until these obesity drugs might be available to patients?
If development continues successfully, these specific compounds would need 3 to 5 years of additional lab testing, then 5 to 10 years of human clinical trials. Realistically, the earliest availability would be 8 to 15 years from now, and these particular drugs may never reach patients.
Want to Apply This Research?
- Track daily energy expenditure and resting metabolic rate using a fitness tracker or smartwatch. Record weekly body weight and fasting blood glucose if you have access to a home glucose monitor. This creates a baseline for comparison if similar drugs become available in the future.
- While waiting for potential future treatments, use the app to log meals and exercise to optimize current metabolic health. Set goals for daily movement and track sleep quality, as both affect mitochondrial function. Monitor how different foods affect your energy levels and blood sugar response.
- Create a long-term health dashboard that tracks weight, energy levels, glucose control, and exercise capacity over months. This personal data will be valuable if you ever participate in clinical trials for new obesity treatments. Share trends with your healthcare provider to guide current treatment decisions.
This research describes experimental drugs tested only in laboratory cells and mice. These compounds do not exist for human use and are not approved by any regulatory agency. Results in animals frequently do not translate to humans. This article is for educational purposes only and should not be interpreted as medical advice or a recommendation to seek these treatments. Anyone with obesity or metabolic concerns should consult with their healthcare provider about proven, currently available treatment options. Do not delay or avoid established medical care based on this early-stage research.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.